The Patterns of Care Data are considered a limited data set and are available via request from the National Cancer Institute (NCI) for researchers who meet the criteria for access to confidential data. For more information on how the data may be obtained please contact Dr. Linda Harlan (<lh50w@nih.gov>).

Introduction {#sec001}
============

Lung cancer is the leading cause of cancer-related mortality in the United States \[[@pone.0156728.ref001]\]. Non-small cell lung cancer (NSCLC), which constitutes over 80% of all lung cancer, is most often diagnosed at advanced stages and, as such, is largely treated with systemic therapy. Although distinct histological subtypes of NSCLC have been recognized since the 1950s, NSCLC was considered a single disease entity in terms of selection of treatment options until the mid-2000s \[[@pone.0156728.ref002]\].

It has since been recognized that a subgroup (10--28%) of NSCLCs have mutations in the epidermal growth factor receptor (*EGFR*) gene that predict sensitivity to EGFR tyrosine kinase inhibitors (TKIs), such as gefitinib, erlotinib or afatinib \[[@pone.0156728.ref003]--[@pone.0156728.ref006]\]. Clinical trials have consistently demonstrated response rates of over 60% with EGFR TKIs in patients with *EGFR*-mutant NSCLC \[[@pone.0156728.ref007]--[@pone.0156728.ref010]\]. Marked improvements in progression-free survival have also been demonstrated with EGFR TKIs over first-line chemotherapy, albeit with no overall survival benefit potentially due to patient crossover from chemotherapy to EGFR TKI \[[@pone.0156728.ref007]--[@pone.0156728.ref010]\]. Erlotinib, afatinib and gefitinib are currently approved in the United States for treatment of patients with advanced, *EGFR*-mutant NSCLC tumors.

The observation that tumor genotype affects treatment response has transformed the recommended care of patients with NSCLC; practice guidelines recommend molecular testing of tumor specimens to inform treatment decisions \[[@pone.0156728.ref011]--[@pone.0156728.ref013]\]. Both the National Comprehensive Cancer Network and American Society of Clinical Oncology guidelines recommended *EGFR* mutation testing for NSCLCs, particularly for advanced, non-squamous tumors \[[@pone.0156728.ref014]--[@pone.0156728.ref015]\]. However, barriers to molecular testing have been identified \[[@pone.0156728.ref016]\] and the patterns of *EGFR* mutation testing and erlotinib treatment in the general population have not previously been described.

The primary aims of this study were to estimate the frequency and determinants of *EGFR* mutation testing and erlotinib treatment among a population-based sample of NSCLC patients. All stages of NSCLC were studied, in order to gain broad insights into community practice. A secondary aim was to determine if *EGFR* mutation status and/or receipt of erlotinib were associated with survival. In order to carry out these research aims, we analyzed data from the most recent National Cancer Institute (NCI) Patterns of Care (POC) lung cancer study. The included participants were diagnosed in 2010 with histologically confirmed NSCLC and were ascertained through the Surveillance, Epidemiology and End Results (SEER) program. When these patients were diagnosed, based on the FDA labeling, erlotinib was the preferred EGFR TKI. Although it was not until 2011 that professional guidelines recommended *EGFR* testing, the utility of *EGFR* testing to predict EGFR TKI sensitivity and the benefits of EGFR TKIs in *EGFR*-mutant tumors were well recognized in 2010 \[[@pone.0156728.ref006],[@pone.0156728.ref007],[@pone.0156728.ref017]--[@pone.0156728.ref019]\]. We believe that the findings described herein provide insights into the early dissemination of NSCLC management practices and could inform ongoing efforts to improve uptake of molecular testing in the general population.

Materials and Methods {#sec002}
=====================

Data source {#sec003}
-----------

A NCI POC study was conducted among NSCLC patients who were ascertained through the SEER program. The SEER program consists of multiple population-based registries that collect data, mainly from hospital records, on incident cancer arising within specified geographic regions across the nation. For this POC study, a random sample of eligible NSCLC SEER patients was selected after stratification by registry, sex and race/ethnicity. To increase precision among minority groups, African Americans, Hispanics, Asian Pacific Islanders (APIs) and American Indians/Native Alaskans (AI/NA) were oversampled. Using survey instruments developed for the POC study, trained abstractors at each registry reviewed medical records and treating physicians were queried. Data were collected at least one year post-diagnosis and included demographics, diagnostics, staging, tumor characteristics and treatment. For more details see [S1 Methods](#pone.0156728.s001){ref-type="supplementary-material"}. Each SEER registry obtained institutional review board approval prior to initiating the POC study.

Study population {#sec004}
----------------

Patients were eligible for the POC study if they were diagnosed in 2010 with invasive, histologically-confirmed, primary NSCLC \[International Classification of Diseases for Oncology, 3rd Edition (ICD-O3): C34.X and 8000--8040, 8046--8671 and 8940--8941\]. Patients were not eligible if they had a history of cancer, except non-melanoma skin cancer, were simultaneously diagnosed with more than one cancer within 60 days, were diagnosed at autopsy or via death certificate only or were younger than 20 years at diagnosis. For the current analyses, patients with neuroendocrine carcinoma, not otherwise specified (ICD-O3: 8246: n = 25) and patients with unknown tumor stage (n = 22) were also excluded.

Statistical analysis {#sec005}
--------------------

To obtain estimates that reflected all eligible NSCLCs diagnosed within the SEER program in 2010, sample weights, defined as the inverse of the sampling proportion for each sampling stratum, were applied. To account for the sample design, all analyses were performed using SAS (version 9.3; SAS Institute Inc., Cary, NC) and SAS-callable SUDAAN (version 10.0.1; Research Triangle Institute, Research Triangle Park, NC).

The weighted percentages of patients who had *EGFR* testing or received erlotinib were calculated among all patients combined and stratified by tumor characteristics (stage, histology and *EGFR* status). Due to the infrequency of *EGFR* testing and administration of erlotinib among patients with non-metastatic disease (stage I-III), subsequent analyses excluded these patients. Among stage IV patients, factors associated with *EGFR* testing and erlotinib treatment were assessed separately. Variables that were associated with either outcome (p\<0.10) based on bivariate Chi-square tests were included in a multivariate logistic model and were retained if they remained significant. The weighted percentage of stage IV patients with *EGFR* mutations was also calculated overall and stratified by race/ethnicity and histology. Finally, whether or not *EGFR* mutation status and/or receipt of erlotinib were associated with all-cause mortality was assessed by constructing a multivariate Cox proportional hazards regression model. Follow-up began on the first day of the month of cancer diagnosis; exact diagnosis date was not available. Survival was calculated through the date of death, date of last contact or December 31, 2011, whichever came first. *EGFR* mutations are known to be more common in adenocarcinomas; therefore, sensitivity analyses were also conducted excluding all non-adenocarcinoma patients. All tests were two sided and statistical significance was assessed using an alpha of 0.05.

Results {#sec006}
=======

Patient demographics and characteristics {#sec007}
----------------------------------------

This study included 1,358 NSCLC patients. The mean age was 67.7 years and 74.6% of patients were over 60 years ([Table 1](#pone.0156728.t001){ref-type="table"}). 54.6% were male and 73.8% were non-Hispanic white. Most patients (82.4%) were smokers and had adenocarcinomas (50.5%). According to the American Joint Committee on Cancer 7th edition (AJCC-7), 26.5% were stage I-II, 18.2% were stage III and 55.3% were stage IV.

10.1371/journal.pone.0156728.t001

###### Demographics and characteristics among sampled patients diagnosed in 2010 with non-small cell lung cancer, Patterns of Care.

![](pone.0156728.t001){#pone.0156728.t001g}

                                                 Total        
  ---------------------------------------------- ------------ ------
  Age at diagnosis                                            
   \<50                                          125          6.3
   50--59                                        287          19.1
   60--69                                        396          30.4
   70--79                                        354          27.8
   80+                                           196          16.4
  Mean (standard error)                          67.7 (0.5)   
  Sex                                                         
   Male                                          690          54.6
   Female                                        668          45.4
  Race/Ethnicity                                              
   Non-Hispanic white                            369          73.8
   Non-Hispanic black                            346          11.3
   Hispanic                                      280          6.9
   API                                           302          7.7
   AI/AN                                         61           0.3
  Ever Smoker                                                 
   No                                            251          12.0
   Yes                                           1036         82.4
   Unknown                                       71           5.6
  Histology                                                   
   Adenocarcinoma                                754          50.5
   Squamous cell                                 331          27.8
   Large cell                                    56           4.7
   Other/not specified                           217          17.0
  Stage, AJCC7                                                
   I -II                                         339          26.5
   III                                           255          18.2
   IV                                            764          55.3
  Charleson comorbidity index                                 
   0                                             621          40.7
   1+                                            737          59.3
  Died within 2 months of diagnosis                           
   No                                            1064         78.8
   Yes                                           294          21.2
  Hospital bed size                                           
   \< 200 beds, out patient only, unknown        282          25.2
   200--299 beds                                 263          18.0
   300--399 beds                                 311          24.3
   400+ beds                                     502          32.5
  Hospital type                                               
   Government, non-federal and federal/unknown   289          20.3
   Non-government, not-for-profit                983          73.2
   Non-government, for-profit                    86           6.5
  Approved residency training program                         
   No/Unknown                                    572          51.0
   Yes                                           786          49.0

AI/NA: American Indians/Native Alaskans; AJCC7: American Joint Committee on Cancer 7th edition; API: Asian Pacific Islander;

^1^ Unweighted total sample size;

^2^ Weighted percentage

Frequency of EGFR testing {#sec008}
-------------------------

Overall 16.8% of NSCLC patients underwent *EGFR* testing ([Table 2](#pone.0156728.t002){ref-type="table"}). When stratified by histology, the frequency of *EGFR* testing ranged from 2.7% among large cell tumors to 20.8% among adenocarcinomas. *EGFR* testing tended to be more likely among patients with stage IV disease (all histologies: 19.9%; adenocarcinomas: 22.6%) but variations across stage did not tend to be statistically significant.

10.1371/journal.pone.0156728.t002

###### Frequency of *EGFR* testing and receipt of erlotinib among non-small cell lung cancer patients diagnosed in 2010 overall and by tumor stage, Patterns of Care.
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                                     Total   Stage I-II   Stage III   Stage IV   
  ---------------------------------- ------- ------------ ----------- ---------- ------------
  Frequency of *EGFR* testing                                                    
  All tumors                         16.8    13.9         11.4        19.9       0.08
   Adenocarcinoma                    20.8    14.4         22.2        22.6       0.23
   Squamous cell                     12.1    19.6         5.1         10.3       0.22
   Large cell                        2.7     0            7.1         1.3        0.28\*
   Other/not specified               16.7    1.4          6.4         26.4       **\<0.01**
  Frequency of erlotinib treatment                                               
  All tumors                         6.3     0.4          6.2         9.2        **\<0.01**
   *EGFR*-mutant                     33.6    0.6          21.8        48.3       **\<0.01**
   *EGFR*-wild type                  5.9     0.0          5.9         8.4        0.44\*
   *EGFR* status unknown             4.8     0.4          5.2         6.9        **\<0.01**

EGFR: epidermal growth factor receptor;

^1^ Weighted percentage;

^2^ Bivariate Chi-square test across all tumor stage or \*between stage III and stage IV

Frequency of erlotinib treatment {#sec009}
--------------------------------

Erlotinib was administered to 6.3% of all NSCLC patients, 33.6% of patients with *EGFR*-mutant tumors, 5.9% of patients with *EGFR*-wild type tumors and 4.8% of patients with unknown *EGFR*-mutant status ([Table 2](#pone.0156728.t002){ref-type="table"}). The receipt of erlotinib, increased significantly with stage among all patients (stage I-II: 0.4%; stage III: 6.2%; stage IV: 9.2%; p\<0.01), among patients with *EGFR*-mutant tumors (stage I-II: 0.6%; stage III: 21.8%; stage IV: 48.3%; p\<0.01) and among patients with tumors of unknown *EGFR* status (stage I-II: 0.4%; stage III: 5.2%; stage IV: 6.9%; p\<0.01).

Determinants of EGFR testing {#sec010}
----------------------------

Among patients with stage IV disease, bivariate analyses indicated that *EGFR* testing was associated with younger age, Hispanic and API heritages, being married, having private/military/other insurance, being a non-smoker, having adenocarcinoma or other/non-specified carcinoma, having no comorbidities and living at least two months after cancer diagnosis ([Table 3](#pone.0156728.t003){ref-type="table"}). Although the likelihood of *EGFR* testing decreased with age, in comparison to patients less than 50 years, multivariate modeling indicated that testing was significantly lower only among patients aged 50--59 \[odds ratio (OR): 0.24; 95% confidence interval (CI): 0.08--0.69\] and 80 years or older (OR: 0.21; 95% CI: 0.06--0.69). *EGFR* testing was also less likely among patients with any Medicaid or no/unknown insurance compared to those with private/military/other insurance (OR range: 0.15--0.20), among patients with large cell tumors compared to those with adenocarcinomas (OR: 0.04; 95% CI: 0.01--0.23), among patients who had comorbidities (OR: 0.33; 95% CI: 0.16--0.68) and patients who died within two months of their cancer diagnosis (OR: 0.24; 95% CI: 0.08--0.73). Additionally, *EGFR* testing was significantly more likely among Hispanics compared to Non-Hispanic whites (OR: 2.54; 95% CI: 1.28--5.03). Among patients with stage IV adenocarcinomas, *EGFR* testing remained significantly more likely among Hispanics, patients with private/military/other insurance and patients with no comorbidities.

10.1371/journal.pone.0156728.t003

###### Factors associated with *EGFR* testing among patients diagnosed in 2010 with stage IV non-small cell lung cancer, Patterns of Care.
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                                                            All   Adenocarcinoma                                                                                 
  --------------------------------------------------------- ----- ---------------- ------------ ---------- ---------------- ----- ------ ------------ ---------- ----------------
  Overall                                                   764   19.9                                                      476   22.6                           
  Age at diagnosis                                                                                                                                               
   \<50                                                     74    43.7             0.08         1.00       ref              47    55.3   0.16                    
   50--59                                                   176   16.6                          **0.24**   **0.08--0.69**   126   20.8                           
   60--69                                                   212   24.0                          0.49       0.18--1.33       131   22.9                           
   70--79                                                   191   16.7                          0.39       0.15--1.05       112   19.6                           
   80+                                                      111   12.3                          **0.21**   **0.06--0.69**   60    13.7                           
  Sex                                                                                                                                                            
   Male                                                     420   19.8             0.95                                     238   25.0   0.51                    
   Female                                                   344   20.1                                                      238   20.5                           
  Race/Ethnicity                                                                                                                                                 
   Non-Hispanic white                                       197   19.1             **\<0.01**   1.00       ref              116   20.7   **0.02**     1.00       ref
   Non-Hispanic black                                       184   12.5                          0.55       0.26--1.15       119   17.3                1.05       0.48--2.30
   Hispanic                                                 167   30.1                          **2.54**   **1.28--5.03**   95    37.8                **2.88**   **1.30--6.37**
   API                                                      185   27.1                          1.68       0.78--3.56       129   31.9                1.89       0.82--4.38
   AI/AN                                                    31    12.6                          0.63       0.12--3.41       17    12.2                0.54       0.06--4.63
  Marital Status                                                                                                                                                 
   Married/Living as                                        354   25.6             **0.05**                                 216   30.2   0.06                    
   Other                                                    410   15.6                                                      260   18.3                           
  Median income, \$[^5^](#t003fn006){ref-type="table-fn"}                                                                                                        
   \>62,000                                                 220   25.0             0.39                                     142   33.7   **0.05**                
   43,000--62,000                                           248   18.5                                                      170   19.5                           
   \< 43,000                                                296   16.5                                                      164   15.5                           
  Insurance                                                                                                                                                      
   Private/Military/Other                                   417   24.6             **\<0.01**   1.00       ref              271   29.7   **0.01**     1.00       ref
   Medicare only                                            114   18.4                          0.89       0.38--2.06       58    14.1                0.57       0.21--1.51
   Any Medicaid                                             180   8.2                           **0.20**   **0.10--0.39**   113   10.0                **0.23**   **0.11--0.45**
   None/unknown                                             53    8.9                           **0.15**   **0.04--0.50**   34    11.3                **0.18**   **0.05--0.61**
  Ever Smoker                                                                                                                                                    
   No                                                       158   36.2             **0.04**                                 121   39.2   0.06                    
   Yes                                                      570   16.5                                                      334   17.5                           
   Unknown                                                  36    33.1                                                      21    40.5                           
  Histology                                                                                                                                                      
   Adenocarcinoma                                           476   22.6             **\<0.01**   1.00       ref                                                   
   Squamous cell                                            123   10.3                          0.47       0.13--4.68                                            
   Large cell                                               37    1.3                           **0.04**   **0.01--0.23**                                        
   Other/not specified                                      128   26.4                          1.15       0.51--2.62                                            
  Charleson comorbidity index                                                                                                                                    
   0                                                        367   29.6             **\<0.01**   1.00       ref              232   34.6   **\<0.01**   1.00       ref
   1+                                                       397   11.9                          **0.33**   **0.16--0.68**   244   12.2                **0.26**   **0.12--0.58**
  Died within 2 months of diagnosis                                                                                                                              
   No                                                       511   26.2             **\<0.01**   1.00       ref              339   28.3   **\<0.01**              
   Yes                                                      253   6.4                           **0.24**   **0.08--0.73**   137   8.3                            
  Hospital bed size                                                                                                                                              
   \< 200 beds, out patient only, unknown                   165   20.0             0.72                                     98    29.2   0.73                    
   200--299 beds                                            156   24.1                                                      101   21.8                           
   300--399 beds                                            179   15.7                                                      107   20.9                           
   400+ beds                                                264   20.8                                                      170   17.8                           
  Hospital type                                                                                                                                                  
   Government, non-federal and federal/unknown              177   26.9             0.33                                     110   28.0   0.67                    
   Non-government, not-for-profit                           536   18.0                                                      334   21.0                           
   Non-government, for-profit                               51    17.8                                                      32    23.5                           
  Approved residency training program                                                                                                                            
   No/Unknown                                               341   16.0             0.10                                     204   20.5   0.43                    
   Yes                                                      423   24.4                                                      272   25.5                           

AI/NA: American Indians/Native Alaskans; API: Asian Pacific Islander; CI: confidence interval; EGFR: epidermal growth factor receptor; OR: odds ratio.

^1^ Unweighted total sample size.

^2^ Weighted percentage that had the test (test positive; test negative; test performed, result unknown)

^3^ Bivariate Chi-square test.\*When Large cell/Other was combined with Carcinoma, NOS

^4^ Logistic regression model adjusting for all variables that were ≤0.10 during univariate analysis and remained significant ≤0.05 in multivariate analyses.

^5^ Based on aggregate data at the census tract level, Census 2000; tertile cut points based on overall weighted distribution.

Frequency of EGFR mutations {#sec011}
---------------------------

Overall 30.4% of the patients with stage IV tumors who underwent *EGFR* testing were found to have an *EGFR* mutation (data not shown). When stratified by race/ethnicity, *EGFR* mutations were least common among non-Hispanic whites (21.2%) compared to Non-Hispanic blacks (42.5%), APIs (49.0%) and Hispanic patients (50.1%). *EGFR* mutations were also more common in adenocarcinomas (35.7%) than squamous cell tumors (9.9%) and tumors of other histology (22.4%).

Determinants of erlotinib treatment {#sec012}
-----------------------------------

Among patients with stage IV disease, treatment with erlotinib was associated with Hispanic and API heritages, not smoking, having an adenocarcinoma, having an *EGFR* mutation, living at least two months after cancer diagnosis and being treated at a larger hospital ([Table 4](#pone.0156728.t004){ref-type="table"}). Multivariate analysis indicated that erlotinib treatment was significantly less likely among smokers compared to non-smokers (OR: 0.27; 95% CI: 0.12--0.59) and patients with other/not specified NSCLC histologies compared to patients with adenocarcinoma (OR: 0.14; 95% CI: 0.04--0.54) and more likely among patients with *EGFR* mutations (OR: 9.90; 95% CI: 3.04--32.24). Among patients with stage IV adenocarcinomas, receipt of erlotinib remained significantly lower among smokers and higher among patients with *EGFR* mutations. Residence in a higher median income area was also significantly associated with receipt of erlotinib. Of patients who received erlotinib, 87.0% of patients with *EGFR*-mutant tumors started erlotinib as their first-line therapy compared to 36.2% of patients with *EGFR* wild-type tumors (data not shown).

10.1371/journal.pone.0156728.t004

###### Factors associated with receipt of Erlotinib among patients diagnosed in 2010 with stage IV non-small cell lung cancer, Patterns of Care.
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                                                                                  All   Adenocarcinoma                                                                                   
  ------------------------------------------------------------------------------- ----- ---------------- ------------ ---------- ----------------- ----- ------ ------------ ----------- -----------------
  Overall                                                                         764   9.2                                                        476   12.4                            
  Age at diagnosis                                                                                                                                                                       
   \<50                                                                           74    16.4             0.41                                      47    23.5   0.26                     
   50--59                                                                         176   5.7                                                        126   7.0                             
   60--69                                                                         212   10.4                                                       131   13.3                            
   70--79                                                                         191   7.4                                                        112   9.3                             
   80+                                                                            111   11.6                                                       60    19.1                            
  Sex                                                                                                                                                                                    
   Male                                                                           420   8.3              0.53                                      238   11.2   0.63                     
   Female                                                                         344   10.2                                                       238   13.5                            
  Race/Ethnicity                                                                                                                                                                         
   Non-Hispanic white                                                             197   6.7              **\<0.01**                                116   9.7    0.06                     
   Non-Hispanic black                                                             184   9.6                                                        119   11.3                            
   Hispanic                                                                       167   16.2                                                       95    23.2                            
   API                                                                            185   23.1                                                       129   25.5                            
   AI/AN                                                                          31    8.9                                                        17    11.6                            
  Marital Status                                                                                                                                                                         
   Married/Living as                                                              354   9.7              0.74                                      216   12.8   0.88                     
   Other                                                                          410   8.7                                                        260   12.2                            
  Median income, \$[^5^](#t004fn006){ref-type="table-fn"}                                                                                                                                
   \>62,000                                                                       220   14.7             0.11                                      142   24.7   **0.02**     1.00        ref
   43,000--62,000                                                                 248   7.0                                                        170   7.1                 **0.30**    **0.11--0.83**
   \< 43,000                                                                      296   6.0                                                        164   6.7                 **0.34**    **0.13--0.91**
  Percentage with a high school education[^5^](#t004fn006){ref-type="table-fn"}                                                                                                          
   \>89%                                                                          331   7.1              0.15                                      206   9.2    0.06                     
   77--89%                                                                        221   5.9                                                        147   7.0                             
   \<77%                                                                          212   13.9                                                       129   20.9                            
  Insurance                                                                                                                                                                              
   Private/Military/Other                                                         417   11.5             0.07                                      271   16.4   0.06                     
   Medicare only                                                                  114   3.7                                                        58    5.1                             
   Any Medicaid                                                                   180   6.9                                                        113   5.7                             
   None/unknown                                                                   53    7.9                                                        34    10.3                            
  Ever Smoker                                                                                                                                                                            
   No                                                                             158   23.8             **\<0.01**   1.00       ref               121   24.8   **\<0.01**   1.00        ref
   Yes                                                                            570   5.9                           **0.27**   **0.12--0.59**    334   7.5                 **0.31**    **0.13--0.73**
   Unknown                                                                        36    24.8                          1.93       0.26--14.53       21    44.0                2.95        0.43--20.09
  Histology                                                                                                                                                                              
   Adenocarcinoma                                                                 476   12.4             **\<0.01**   1.00       ref                                                     
   Squamous cell                                                                  123   5.9                           0.70       0.19--2.52                                              
   Large cell                                                                     37    8.7                           1.08       0.15--8.09                                              
   Other/not specified                                                            128   2.0                           **0.14**   **0.04--0.54**                                          
  *EGFR* mutation                                                                                                                                                                        
   Negative                                                                       84    8.4              **\<0.01**   1.00       ref               63    10.3   **0.01**     1.00        ref
   Positive                                                                       68    48.3                          **9.90**   **3.04--32.24**   54    58.3                **14.46**   **3.59--58.22**
   Unknown                                                                        612   6.9                           0.72       0.27--1.93        359   9.0                 0.89        0.24--3.48
  Charleson comorbidity index                                                                                                                                                            
   0                                                                              367   11.9             0.13                                      232   16.1   0.18                     
   1+                                                                             397   6.9                                                        244   9.1                             
  Died within 2 months of diagnosis                                                                                                                                                      
   No                                                                             511   11.5             **0.03**                                  339   14.2   0.27                     
   Yes                                                                            253   4.1                                                        137   7.8                             
  Hospital bed size                                                                                                                                                                      
   \< 200 beds, out patient only, unknown                                         165   8.6              **0.04**                                  98    8.7    **0.05**                 
   200--299 beds                                                                  156   13.4                                                       101   18.4                            
   300--399 beds                                                                  179   4.3                                                        107   6.4                             
   400+ beds                                                                      264   11.1                                                       170   16.3                            
  Hospital type                                                                                                                                                                          
   Government, non-federal and federal/unknown                                    177   7.6              0.48                                      110   11.9   0.73                     
   Non-government, not-for-profit                                                 536   8.1                                                        334   11.1                            
   Non-government, for-profit                                                     51    25.5                                                       32    26.4                            
  Approved residency training program                                                                                                                                                    
   No/Unknown                                                                     341   9.0              0.90                                      204   10.5   0.30                     
   Yes                                                                            423   9.4                                                        272   15.0                            

AI/NA: American Indians/Native Alaskans; API: Asian Pacific Islander; CI: confidence interval; OR: odds ratio.

^1^ Unweighted total sample size.

^2^ Weighted percentage that received Erlotinib.

^3^ Bivariate Chi-square test.

^4^ Logistic regression model adjusting for all variables that were ≤0.10 during univariate analysis and remained significant ≤0.05 in multivariate analyses.

^5^ Based on aggregate data at the census tract level, Census 2000; tertile cut points based on overall weighted distribution.

Survival {#sec013}
--------

Among patients with stage IV disease, *EGFR*-mutant tumors and treatment with erlotinib were both associated with better survival during bivariate analyses ([Table 5](#pone.0156728.t005){ref-type="table"}). However, in multivariate analyses, neither retained survival significance. Among patients with stage IV adenocarcinomas, patients with *EGFR*-mutant tumors had a better survival \[Hazard Ratio (HR): 0.43; 95% CI: 0.24--0.76\]; again, receipt of erlotinib was not associated with survival.

10.1371/journal.pone.0156728.t005

###### Association between *EGFR*-mutant status and Erlotinib treatment with all-cause survival among patients diagnosed in 2010 with stage IV non-small cell lung cancer, Patterns of Care.
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                    All   Adenocarcinoma                                                                                 
  ----------------- ----- ---------------- ------------ ---------- ---------------- ----- ------ ------------ ---------- ----------------
  *EGFR* mutation                                                                                                        
   Negative         84    66.3             **\<0.01**   1.00       ref              63    73.0   **\<0.01**   1.00       ref
   Positive         68    45.6                          0.64       0.35--1.18       54    32.1                **0.43**   **0.24--0.76**
   Unknown          612   86.0                          **1.59**   **1.18--2.14**   365   81.6                1.06       0.71--1.58
  Erlotinib                                                                                                              
   No, unknown      662   83.6             **0.01**     1.00       ref              401   79.7   **0.04**     1.00       ref
   Yes              102   63.0                          0.69       0.47--1.02       81    60.2                0.69       0.47--1.03

EGFR: epidermal growth factor receptor; CI: confidence interval; HR: hazard ratio.

^1^ Unweighted total sample size.

^2^ Weighted percentage of patients who had died as of December 31, 2011.

^3^ Bivariate Chi-square test by vital status as of December 31, 2011.

^4^ Hazard ratio from Cox proportional hazard model adjusting for age, sex, race/ethnicity, marital status, residential income level, insurance status, ever smoking status, Charlson comorbidity index, *EGFR* status, receipt of Erlotinib, surgery, radiotherapy, other systemic therapy, and hospital characteristics (bed size, classification, residency program)

Discussion {#sec014}
==========

This study establishes the general population-based patterns of *EGFR* mutation testing and treatment with erlotinib for NSCLC in the United States in 2010. An estimated 16.8% of all newly diagnosed NSCLC patients underwent *EGFR* mutation testing. Among patients with stage IV tumors, *EGFR* testing varied significantly by age, insurance and comorbidity level. Furthermore, an estimated 33.6% of NSCLC patients with *EGFR*-mutant tumors received erlotinib, which was also administered to 5.9% of NSCLC patients with *EGFR*-wild type tumors. Among patients with stage IV tumors, erlotinib treatment was less likely among smokers and patients with non-adenocarcinomas. *EGFR*-mutation was associated with improved survival, albeit only among stage IV adenocarcinomas.

The reason why a large proportion of patients with stage IV disease in the current study were not assessed for *EGFR* mutations is likely multifactorial. For example, assay costs and issues related to tissue acquisition and turnaround time may have contributed to the low testing rate \[[@pone.0156728.ref020],[@pone.0156728.ref021]\]. Additionally, and maybe more importantly, professional guidelines did not recommend routine testing for *EGFR* mutations until 2011 \[[@pone.0156728.ref011]--[@pone.0156728.ref013]\]. However, given that the benefit of *EGFR*-directed therapy in selected patients was recognized well before professional societies formally recommended testing, it was still surprising that less than a quarter of the patients underwent *EGFR* testing in 2010.

More concerning is our finding of significant disparities in *EGFR* mutation testing. In addition to observing variations by health insurance status, comorbidity and older age were associated with significantly lower *EGFR* mutation testing rates. Although aggregate residential income level was not associated with *EGFR* testing rates, it cannot be ruled out that the association with insurance status may at least partially be due to confounded by unmeasured variations in patient-level variables (e.g., income and education). The observed variations in *EGFR* testing rates by insurance status may also reflect the fact that professional guidelines, which can impact insurance coverage policy, had yet to recommend routine *EGFR* testing by 2010. It is worth noting however that previous POC analyses have indicated that patients with Medicaid or Medicare-only are often under treated \[[@pone.0156728.ref022]\]; thus, our results may extend these findings to the realm of molecular testing. Given the manageable toxicity profile and higher efficacy compared with chemotherapy, EGFR TKIs are recommended in patients with tumors harboring *EGFR* sensitizing mutations regardless of their performance status \[[@pone.0156728.ref023]\]. Sustained, clinically relevant improvements in quality of life have been observed in patients with *EGFR-*mutant tumors after EGFR TKIs treatment compared to chemotherapy \[[@pone.0156728.ref007]\]. Our data indicates that in the general practice, comorbid conditions and limited life expectancy, both surrogates for poor performance status, were significant negative determinants of *EGFR* mutation testing. Although the progression-free survival benefits associated with erlotinib have not been found to vary by age, greater toxicities have been observed among older patients \[[@pone.0156728.ref024]\]. Therefore, the anticipation of greater toxicities with erlotinib among older patients may explain why older age was associated with a lower likelihood of *EGFR* testing.

Disparities were also observed for the receipt of erlotinib related to smoking status and possibly median residential income level. Although further studies are needed to confirm these findings, it is possible that clinicians are less inclined to administer erlotinib to smokers because smoking increases the metabolic clearance of erlotinib and, thereby, diminishes the effectiveness \[[@pone.0156728.ref025]\]. The finding that lower income patients were less likely to receive erlotinib may be a true indication of a cost barrier. However, this finding should be interpreted cautiously because individual income level was not available.

The incidence of *EGFR* mutation varies by race/ethnicity. Previous studies have estimated that 15--20% of white and 50--55% of API NSCLC patients have *EGFR*-mutant tumors \[[@pone.0156728.ref026]--[@pone.0156728.ref029]\]. The frequency of *EGFR* mutations among African American and Hispanic NSCLC patients is less clear. Possibly due to small sample sizes and heterogeneity across studies, the frequency of *EGFR*-mutant tumors among African American NSCLC patients has ranged between 2--20% \[[@pone.0156728.ref026]--[@pone.0156728.ref030]\]. Only one study has assessed the frequency of *EGFR*-mutant NSCLC in Hispanic patients (15%) \[[@pone.0156728.ref031]\]. In contrast to these previous studies, the frequency of *EGFR*-mutant tumors in this study was assessed among patients selected on the basis of clinico-pathologic characteristics (e.g., patients with adenocarcinomas and/or non-smokers were more likely to have an *EGFR* test). Thus, the observed frequencies in the current study demonstrate selective testing tends to enrich the frequency of *EGFR*-mutant tumors, particularly among non-Hispanic black and Hispanic patients. Higher than expected frequencies of *EGFR*-mutant tumors among non-Hispanic black and Hispanic patients, may be largely due to racial/ethnic variation in smoking and histology. For example, Hispanic patients were less likely to be smokers than NHW (71.1% vs. 85.4%, respectively, p\<0.01) and Hispanic and non-Hispanic black patients were more likely to have had adenocarcinomas than NHW patients (56.7%, 57.5% and 48.5%, respectively p≤0.14; data not shown).

Albeit only among patients with stage IV adenocarcinomas, we found that *EGFR*-mutant tumors were associated with better survival. This finding is consistent with previous reports in patients with advanced NSCLC, which suggest that *EGFR* mutation status by itself is a favorable prognostic marker \[[@pone.0156728.ref032],[@pone.0156728.ref033]\]. Erlotinib was not independently associated with survival. However, due to the high frequency of patients in whom *EGFR* testing was not done, the small number of patients with *EGFR* mutations and the observational nature of this study, which makes it prone to confounding by indication, these results should be interpreted with caution.

To our knowledge only a limited number of prior studies have addressed the question of adoption of *EGFR* mutation testing in general practice. Based on retrospective data from the US Oncology Network data, Pan et al. estimated that 15.2% of patients with stage IV NSCLC underwent *EGFR* testing and that 50.0% of patients with stage IV *EGFR*-mutant tumors received erlotinib \[[@pone.0156728.ref034]\]. Our results which are based on a larger, population-based sample are consistent with these findings.

The current study also provides data on *EGFR* mutation testing and erlotinib use among patients with early-stage NSCLC, a group for which current guidelines do not recommend testing or treatment \[[@pone.0156728.ref013],[@pone.0156728.ref026]\]. Interestingly, 13.9% of NSCLC patients with stage I-II disease received *EGFR* mutation testing. Notwithstanding the relatively high frequency of *EGFR* mutation testing in this population, a very low number of the patients received erlotinib. The role of adjuvant erlotinib in NSCLC remains under investigation (NCT02194738).

The strengths of this study include the population-based data, oversampled minority groups, and physician verified treatment. This study had several limitations. We were not able to assess all factors that may have influenced the decisions to have *EGFR* testing or treatment with erlotinib. For example, tumors that were classified as non-adenocarcinoma may have had an adenocarcinoma component, which may partially explain the higher than expected frequency of *EGFR* mutations among the non-adenocarcinoma categories. Additionally, we were not able to assess how testing and subsequent treatment were impacted by inadequate tissue samples and variable laboratory turnaround times. Variations by specific mutation were also not assessable because this information was not recorded. Additionally, small sample size precluded the ability to identify factors associated with *EGFR* testing and receipt of erlotinib among patients with earlier stage tumors and non-adenocarcinomas. Small sample size may also have impacted the observed mutation rate among racial subgroups. Finally, because NSCLC has not been selected as a POC study cancer site since 2010, it was not possible to assess more recent clinical practices. It is likely that *EGFR* testing frequency has increased in the recent years with it being recommended by professional societies \[[@pone.0156728.ref011],[@pone.0156728.ref012]\]. Despite the limitations, we were able to examine *EGFR* testing and erlotinib use among NSCLC patients that were representative of those seen in the general clinical practice.

In conclusion, targeted therapy in molecularly selected patients is transforming lung cancer treatment. Although the current testing rates are likely substantially higher than rates reported here, the results from the current study indicate patterns of early dissemination of *EGFR* mutation testing and erlotinib treatment. The complexity of testing and treatment for lung cancer patients will likely increase as additional targets and therapies are identified. A national strategy is imperative to ensure that resources and processes are in place to more widely implement molecular testing.
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